IMRT Plus PD-1 Blockade and Lenvatinib for HCC With PVTT (Vp3) Before Liver Transplantation
Status:
Not yet recruiting
Trial end date:
2024-05-31
Target enrollment:
Participant gender:
Summary
This is a single arm, open-label, perspective trial studying the safety and efficacy of
intensity-modulated radiotherapy (IMRT) combined with PD-1 Blockade and Lenvatinib for
Hepatocellular Carcinoma (HCC) with Vp3 Portal Vein Tumor Thrombus (PVTT, Japanese Liver
Cancer Study Group classification) before liver transplantation.